Extra references
  1. Zijlstra EE, Ali MS, el Hassan AM, Toum IA, Satt M, Ghalib HW, et al. Kala-azar: a comparative study of parasitological methods and direct agglutination test in diagnosis. Trans R. Soc Trop Med Hyg 1992;86:505-7.
  2. Jelinek T, Eichenlaub S, Loscher T. Sensitivity and specificity of a rapid immunochromatographic test for diagnosis of visceral leishmaniasis. Eur J Clin Microbiol Infect Dis 1999;18:669-70.
  3. Alvar J, Canavata C, Gutierreez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, et al. Leishmania and human immunodeficiency virus co-infection: the first 10 years. Clin Microbiol Rev 1997;10:298-319.
  4. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999;180:564-7.
  5. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus Sbv in first line treatment of Indian kala-azar. Lancet 1994;344:1599-600.
  6. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998;352:1821-3.
  7. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001;65:685-9.
  8. Desjeux P, Piot B, O’Neill K, Meert JP. Co-infections of leishmania/HIV in south Europe. Med Trop (Mars) 2001;61:187-93.
  9. Berman JD. Treatment of New World cutaneous and mucosal leishmaniases. Clin Dermatol 1996;14:519-22.
  10. El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992;27:227-31.
  11. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001;65:466-70.
  12. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002;66:147-51.
  13. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992;165:528-34.
  14. Kelly DW, Mustafa Z, Dye C. Differential application of lambdacyhalothrin to control the sandfly Lutzomyia longipalpis. Med Vet Entomol 1997;11:13-24.
  15. Gomes AC, Neves VLFC. Estrategia e pespectivas de controle da leishmaniose tegumantar no Estada de Sao Paulo. Revist Inst Med Trop Sao Paulo 1998;31:553-8.
  16. Davies CR, Llanos-Cuentas A, Canales J, Leon E, Alvarez E, Monje J, et al. The fall and rise of Andean cutaneous leishmaniasis: transient impact of the DDT campaign in Peru. Trans R Soc Trop Med Hyg 1994;88:389-93.
  17. Alexander B, Usma MC, Cadena H, Quesada BL, Solarte Y, Roa W, et al. Evaluation of deltamethrin-impregnated bednets and curtains against phlebotomine sandflies in Valle del Cauca, Colombia. Med Vet Entomol 1995;9:279-83.
  18. El Naiem DA, Elnaha AM, Aboud MA. Protective efficacy of lambdacyhalothrin-impregnated bednets against Phlebotomus orientalis, the vector of visceral leishmaniasis in Sudan. Med Vet Entomol 1999;13:310-4.
  19. Nadim A, Motabar M, Hoishmand B, Keyghobadi K, Aflotonian MR. Evaluation of pyrethroid impregnated bednets for control of anthroponotic cutaneous leishmaniasis in Bam (Islamic Republic of Iran). Geneva: World Health Organization, 1995. (WHO/LEISH/95.37.)
  20. Kroeger A, Villegas Avila E, Morison L. Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: cluster randomised trial. BMJ 2002;325:810-3.
  21. Courtenay O, Quinnell RJ, Garcez LM, Shaw JJ, Dye C. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 2002;186:1314-20.
  22. Braga MD, Coelho IC, Pompeu MM, Evans TG, MacAullife IT, Teixeira MJ, et al. Control of canine visceral leishmaniasis: comparison of results from a rapid elimination program of serum-reactive dogs using an immunoenzyme assay and slower elimination of serum-reactive dogs using filter paper elution indirect immunofluorescence. Rev Soc Bras Med Trop 1998;31:419-24.
  23. Guanghua X, Changfa J, Yumei H, Peize X, Weikuan X, Anzhi Z, et al. Studies on the deltamethrin-medicated bath of domestic dogs for interrupting visceral leishmaniasis transmission. Chin J Parasitol Parasit Dis 1995;13:178-81.
  24. David JR, Stamm LM, Bezarra HS, Souza RN, Killick-Kendrick R, Lima JW. Deltamethrin-impregnated dog collars have a potent anti-feeding and insecticidal effect on Lutzomyia longipalpis and Lutzomyia migonei. Mem Inst Oswaldo Cruz 2001;96:839-47.
  25. Maroli M, Mizzoni V, Siragusa C, D’Oraz A, Gradoni L. Evidence for an impact on the incidence of canine leishmaniasis by the mass use of deltamethrin-impregnated dog collars in southern Italy. Med Vet Entomol 2001;15:358-63.
  26. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998;351:1540-3.
  27. Gonzalo RM, del Real G, Rodriguez JR, Rodriguez D, Heljasvaara R, Lucas P, et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 2002;20:1226-31.
  28. Da Silva VO, Borja-Cabrera GP, Correia Pontes NN, de Souza EP, Luz KG, Palatnik M, et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 2000;19:1082-92.
  29. Reed SG. Leishmaniasis vaccination: targeting the source of infection. J Exp Med 2001;194:F7-9.
  30. Valenzuela JG, Belkaid Y, Garfield MK, Mendez S, Kamhawi S, Rowton ED, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001;194:331-42.